The Genomics in Cancer Care Market reached USD 13.4 billion in 2022 and is projected to grow to USD 51.1 billion by 2031, exhibiting a CAGR of 18.9% during the forecast period 2024–2031, driven by the growing role of precision medicine and targeted therapies in oncology. Genomic testing helps identify cancer-causing mutations, such as BRCA1 and BRCA2, enabling accurate diagnosis, prognosis, and treatment selection. By uncovering genetic changes in cancer cells, genomics supports the development of more effective, individualized therapies that significantly improve patient outcomes and survival rates.

Unlock exclusive insights with our detailed sample report :

https://www.datamintelligence.com/download-sample/genomics-in-cancer-care-market

Key Market Drivers

1. Rising Global Cancer Prevalence

According to WHO, cancer is a leading cause of death globally, with over 20 million new cases expected annually by 2030. This has created a demand for advanced genomic tools that facilitate early detection and personalized treatment strategies.

2. Advances in NGS and Genomic Sequencing

Technological breakthroughs in whole genome sequencing (WGS), targeted gene panels, and RNA sequencing are enhancing the ability to identify key mutations and develop tailored therapeutic approaches.

3. Shift Toward Precision Oncology

The era of one-size-fits-all cancer treatment is fading. Genomic testing enables oncologists to match therapies based on individual molecular profiles, increasing treatment success rates and reducing adverse effects.

4. Integration of AI and Machine Learning

AI-driven platforms are accelerating genomic data interpretation, assisting in variant classification, biomarker discovery, and real-time decision-making for clinicians and researchers.

5. Government and Industry Investments

Public and private investments are growing rapidly. For example:

• The U.S. Cancer Moonshot initiative continues to support genomic cancer research.
• Japan’s Genomic Medicine Plan is focused on nationwide whole-genome sequencing efforts and biomarker development.

Regional Highlights

United States

• The U.S. is at the forefront of genomic integration in cancer care, with extensive use of NGS panels, companion diagnostics, and cloud-based genomic tools.
• Leading institutions like Memorial Sloan Kettering and MD Anderson partner with biotech firms for tumor sequencing projects.
• The FDA has increased approval of genomic-based cancer therapies and companion diagnostics, ensuring regulatory clarity and accelerating innovation.

Japan

• Japan is heavily investing in aging-focused cancer genomics as over 28% of its population is aged 65 or above.
• National cancer programs promote biobank development, data-sharing frameworks, and personalized therapeutic protocols.
• Hospitals are piloting AI-integrated genomic dashboards to aid clinical decision-making for oncologists.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements:

https://www.datamintelligence.com/customize/genomics-in-cancer-care-market

Key Segments

By Technology:

• Next-Generation Sequencing (NGS)
• PCR (Polymerase Chain Reaction)
• Microarrays
• Sanger Sequencing

By Application:

• Diagnostics
• Drug Discovery and Development
• Prognostics and Screening
• Companion Diagnostics

By Cancer Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Others (Melanoma, Leukemia, etc.)

By End-User:

• Hospitals & Clinics
• Academic & Research Institutes
• Biotech & Pharma Companies
• Diagnostic Labs

Recent Industry Developments

1. Thermo Fisher Scientific launched an expanded NGS panel approved for solid tumors, improving turnaround times and reducing costs in hospitals.
2. Roche and Foundation Medicine extended collaboration to develop comprehensive genomic profiling (CGP) solutions for rare cancers.
3. Illumina and AstraZeneca announced a joint platform that integrates genomic sequencing with drug development, accelerating targeted therapy pipelines.
4. Japan’s National Cancer Center began a trial for population-level cancer genome screening, a first in Asia-Pacific’s clinical genomics ecosystem.
5. The NIH’s All of Us Research Program now includes cancer patients in its longitudinal genomic dataset, broadening ethnic and genetic diversity.

Buy the exclusive full report here:

https://www.datamintelligence.com/buy-now-page?report=genomics-in-cancer-care-market

Growth Opportunities

• Expansion of Liquid Biopsy Testing: Non-invasive blood-based genomic testing is opening doors for real-time tumor monitoring and minimal residual disease detection.
• Development of Multi-Cancer Early Detection (MCED) Tests: These tests use genomic signals to detect various cancer types at once, revolutionizing preventive oncology.
• Decentralized Genomic Testing Platforms: The adoption of cloud and edge computing in diagnostics supports genomic data analysis even in smaller hospitals.
• Increasing Partnerships with Pharma: Biopharma companies seek genomic data insights to design better trials, improving drug response and reducing trial failure rates.
• Personalized Cancer Vaccines: Genomics is paving the way for neoantigen-based immunotherapies, which are now entering clinical trials globally.

Challenges and Considerations

• High Costs of Sequencing: Despite decreasing, comprehensive genomic profiling remains expensive and is not uniformly reimbursed.
• Data Privacy Concerns: Handling of sensitive genomic data raises questions around patient consent, security, and ownership.
• Skill Gaps in Data Interpretation: Many healthcare providers still lack the training required to interpret complex genomic reports accurately.

Leading Market Players

• Illumina, Inc.
• Thermo Fisher Scientific
• Agilent Technologies
• Roche Diagnostics
• Bio-Rad Laboratories
• Qiagen N.V.
• Foundation Medicine
• Guardant Health
• Fujifilm Holdings Corp. (Japan)

These companies are:

• Launching multi-cancer panels
• Building AI-enabled interpretation platforms
• Partnering with governments and hospitals for clinical validation
• Focusing on affordability and access in underserved regions

Stay informed with the latest industry insights-start your subscription now:

https://www.datamintelligence.com/reports-subscription

Conclusion

The genomics in cancer care market is not just expanding—it’s transforming the very fabric of oncology. From tumor characterization to tailored therapies, genomics is enabling a future where cancer care is not only more effective but also more humane and precise.

With growing government support, rapid adoption of AI tools, and unprecedented collaboration between diagnostics and therapeutics, the global healthcare ecosystem is on the brink of genomic-enabled cancer care at scale.

The next decade will not just be about treating cancer—but about predicting, preventing, and personalizing the battle against it.

About us:

DataM Intelligence is a premier provider of market research and consulting services, offering a full spectrum of business intelligence solutions—from foundational research to strategic consulting. We utilize proprietary trends, insights, and developments to equip our clients with fast, informed, and effective decision-making tools.

Our research repository comprises more than 6,300 detailed reports covering over 40 industries, serving the evolving research demands of 200+ companies in 50+ countries. Whether through syndicated studies or customized research, our robust methodologies ensure precise, actionable intelligence tailored to your business landscape.

Contact US:

Company Name: DataM Intelligence

Contact Person: Sai Kiran

Email: sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com